Karenitecin in Treating Patients With Recurrent Malignant Glioma

NCT00014521 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

NIH

Sponsor class

Conditions

Brain and Central Nervous System Tumors

Interventions

DRUG: karenitecin

Sponsor

National Cancer Institute (NCI)